Jasper Therapeutics, Inc. (JSPR) Ownership
JSPR ownership summary
as of October 17, 2026- Institutions
- 39.3% of shares outstanding
- Insiders
- 2.86% of shares outstanding
- Shares outstanding
- 33.3M
- Float
- 30.0M shares available to trade
- Short interest
- 19.24% 6.2M shares short
- Days to cover
- 16.16 short interest up 7.1% vs prior month
- Institutions 39.27%
- Insiders 2.86%
- Other investors 57.87%
JSPR top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Velan Capital Investment Management LP | 8.02% | 2.7M | $1.3M | — | June 30, 2026 |
| 2 | Kingdon Capital Management LLC | 4.06% | 1.4M | $649,011 | — | June 30, 2026 |
| 3 | Vanguard Capital Management, LLC | 3.52% | 1.2M | $562,570 | −576 (−0.0%) | June 30, 2026 |
| 4 | Rock Springs Capital Management LP | 3.31% | 1.1M | $528,348 | — | June 30, 2026 |
| 5 | The Carlyle Group Inc | 3.20% | 1.1M | $511,771 | — | June 30, 2026 |
| 6 | GSA Capital Partners LLP | 1.61% | 535K | $256,655 | +515,613 (+2,701.8%) | June 30, 2026 |
| 7 | Millennium Management LLC | 1.46% | 487K | $233,728 | −1.1M (−69.9%) | June 30, 2026 |
| 8 | Lion Point Capital, LP | 1.40% | 465K | $223,200 | — | June 30, 2026 |
| 9 | Geode Capital Management, LLC | 0.79% | 264K | $126,628 | −53,869 (−17.0%) | June 30, 2026 |
| 10 | Renaissance Technologies Corp | 0.71% | 238K | $114,192 | +60,400 (+34.0%) | June 30, 2026 |
| 11 | BlackRock Inc | 0.51% | 170K | $81,421 | −72,434 (−29.9%) | June 30, 2026 |
| 12 | Vanguard Fiduciary Trust Co | 0.45% | 150K | $71,973 | — | June 30, 2026 |
| 13 | ADAR1 Capital Management LLC | 0.42% | 140K | $67,200 | — | June 30, 2026 |
| 14 | Quarry LP | 0.40% | 132K | $63,134 | — | June 30, 2026 |
| 15 | Jane Street Group LLC | 0.31% | 102K | $48,837 | +80,328 (+375.1%) | June 30, 2026 |
| 16 | UBS Group AG | 0.18% | 59K | $28,204 | −22,358 (−27.6%) | June 30, 2026 |
| 17 | Jain Global LLC | 0.15% | 51K | $24,569 | +33,163 (+184.0%) | June 30, 2026 |
| 18 | Advisor Group Holdings, Inc. | 0.14% | 46K | $22,008 | +5,000 (+12.2%) | June 30, 2026 |
| 19 | State Street Corp | 0.13% | 45K | $21,456 | — | June 30, 2026 |
| 20 | Northern Trust Corp | 0.13% | 42K | $20,103 | +7,306 (+21.1%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 6 holders added 702K shares and 5 cut 1.3M.
JSPR top mutual fund and ETF holders
6 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.50% | 833K | $400,028 | — | August 31, 2026 |
| 2 | Fidelity Extended Market Index | 0.49% | 163K | $78,299 | +35,597 (+27.9%) | August 31, 2026 |
| 3 | Fidelity Total Market Index | 0.15% | 50K | $23,950 | — | August 31, 2026 |
| 4 | Fidelity Series Total Market Index | 0.10% | 34K | $16,372 | — | August 31, 2026 |
| 5 | Vanguard Balanced Index Inv | 0.08% | 27K | $12,767 | — | August 31, 2026 |
| 6 | Knights of Columbus U.S. All Cap Idx I | <0.01% | 155 | $74 | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
JSPR insider transactions
latest 4| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2025-09-22 | Judith Anne Shizuru | Buy | $2.43 | 41,000 | $99,630 |
| 2025-09-22 | Ron Martell | Buy | $2.43 | 41,000 | $99,630 |
| 2025-09-22 | Svetlana Lucas | Buy | $2.43 | 20,000 | $48,600 |
| 2025-09-22 | Thomas G Wiggans | Buy | $2.43 | 41,000 | $99,630 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
JSPR shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns JSPR
Institutional investors own 39.3% of Jasper Therapeutics's shares and insiders 2.86%. The largest holder is Velan Capital Investment Management LP with 8.02% of the shares (2.7M), as of June 30, 2026. Among the top 20 institutions, 6 added shares and 5 reduced their stake in the latest filings. Short interest is 19.24% of the float, or 16.16 days of average trading volume. The share count rose 15,461.1% since 2020.
Related: JSPR analyst forecast, JSPR key metrics. See the JSPR stock overview for the latest quote and news.
JSPR ownership FAQ
Who owns the most Jasper Therapeutics stock?
The largest shareholders of Jasper Therapeutics are Velan Capital Investment Management LP (8.02%), Kingdon Capital Management LLC (4.06%), Vanguard Capital Management, LLC (3.52%), Rock Springs Capital Management LP (3.31%), The Carlyle Group Inc (3.20%).
What percentage of Jasper Therapeutics is owned by institutions?
Institutions hold 39.3% of Jasper Therapeutics's shares outstanding; insiders hold 2.86%.
Which funds own Jasper Therapeutics?
The largest fund holders of Jasper Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (2.50%), Fidelity Extended Market Index (0.49%), Fidelity Total Market Index (0.15%), Fidelity Series Total Market Index (0.10%), Vanguard Balanced Index Inv (0.08%).
What is Jasper Therapeutics's short interest?
6.2M shares of Jasper Therapeutics were sold short, 19.24% of the float; at the average daily volume it would take 16.16 days to cover.
Are insiders buying or selling Jasper Therapeutics?
Of the latest 4 reported insider transactions in Jasper Therapeutics (since September 22, 2025), 4 were purchases and 0 were sales.
How many shares of Jasper Therapeutics are outstanding?
Jasper Therapeutics has 33.3M shares outstanding, of which 30.0M are in the public float.